26 May 2013
Keywords: novexel, nxl104, enters, ph, testing, paris, france-based
Article | 22 December 2006
Paris, France-based Novexel says that its beta-lactamase inhibitor, NXL104, has advanced into Phase I clinical testing. The firm noted that
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
22 January 2007
24 May 2013
© 2013 thepharmaletter.com